Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26110659 | 1.00 | TSHR (0.33) | TSHRMAPTCHRM4CHRM3GAA | |
| SCHEMBL31665062 | 1.00 | TSHR (0.33) | TSHRMAPTCHRM4CHRM3GAA | |
| SCHEMBL799017 | 0.80 | SMN1; SMN2 (0.43) | TSHRMAPTGAASMN1; SMN2RECQL | |
| SCHEMBL18081175 | 0.80 | SMN1; SMN2 (0.43) | TSHRMAPTGAASMN1; SMN2RECQL | |
| SCHEMBL27544882 | 0.80 | TSHR (0.33) | TSHRMAPTGAASMN1; SMN2RECQL | |
| SCHEMBL25249044 | 0.80 | TSHR (0.33) | TSHRMAPTGAASMN1; SMN2RECQL | |
| SCHEMBL26241593 | 0.80 | SMN1; SMN2 (0.43) | TSHRMAPTGAASMN1; SMN2RECQL | |
| SCHEMBL357505 | 0.80 | SMN1; SMN2 (0.43) | TSHRMAPTGAASMN1; SMN2RECQL | |
| SCHEMBL22576796 | 0.80 | TSHR (0.33) | TSHRMAPTGAASMN1; SMN2RECQL | |
| SCHEMBL29412339 | 0.78 | MAPT (0.32) | TSHRMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| US-8603975-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2013-12-10 | — | — | US | disclosed |
| EP-2150269-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-11-21 | — | — | EP | disclosed |
| EP-2455098-A1 | New cyclic peptide compounds | Astellas Pharma Inc. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, ZC3HAV1 | TSHR 2794/4885MAPT 4380/4885CHRM4 4823/4885 |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | TSHR 4555/4885MAPT 3168/4885CHRM4 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.